Bingsong Han

This inventor holds 77 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in HDAC Inhibitors (CPC class C07D). Top assignees: Forma Therapeutics, Inc., Valo Health, Inc., Forma Tm, LLC. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bingsong Han. Retrieved from https://idiyas.com/inventor/bingsong-han

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 77 (Patent Applications = 12)

% Patents Active = 93.5

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 8 (Patent Applications = 17)

Average Co-Inventor Count = 9.1

ph-index = 14

Forward Citations = 646(Granted Patents)

Forward Citations (Not Self Cited) = 248(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Hamden, CT (US) (2005 - 2012)
North Haven, CT (US) (2007 - 2019)
Watertown, MA (US) (2017 - 2020)
Westwood, MA (US) (2019 - 2024)

Company Filing History:

35 out of 125

Forma Therapeutics, Inc.

Valo Early Discovery, Inc.

patents

7. 4 out of 89

Novo Nordisk Healthcare Ag

patents

8. 1 out of 312

H. Lee Moffitt Cancer Center and Research Institute, Inc.

patents

9. 1 out of 29

Novartis International Pharmaceutical, Ltd.

patents

10. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

HDAC Inhibitors

NAMPT Inhibition

Pyruvate Kinase Activators

USP36

USP19

Isoindolines

Piperidine Derivatives

Bicyclic Hydroxamic Acids

Alpha-Cinnamide Compounds

3-Aryl Compounds

4-Amido Compounds

Sickle Cell Disease

77 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760027 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2026-10-13),

2. 12590087 - Inhibiting USP36 (2026-03-31),

3. 12479807 - METHODS USING HDAC11 INHIBITORS (2025-11-25),

4. 12336981 - Compounds and compositions for the inhibition of NAMPT (2025-06-24),

5. 12264137 - 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2025-04-01),

6. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2024-08-27),

7. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-08-06),

8. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound (2024-05-14),

9. 11919839 - Alpha-cinnamide compounds and compositions as HDAC8 inhibitors (2024-03-05),

10. 11891365 - 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors (2024-02-06),

11. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators (2023-05-16),

12. 11547701 - Compounds and compositions for the inhibition of NAMPT (2023-01-10),

13. 11535607 - Isoindolines as HDAC inhibitors (2022-12-27),

14. 11479564 - Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT) (2022-10-25),

15. 11414392 - [6,6] fused bicyclic HDAC8 inhibitors (2022-08-16),

Title: Bingsong Han: Innovator in Pyruvate Kinase Research

Introduction

Bingsong Han is a prolific inventor based in Westwood, MA, with an impressive portfolio of 72 patents to his name. His contributions to the field of biochemistry and medicine, particularly concerning pyruvate kinase, have positioned him as a key player in developing novel therapeutic strategies for various diseases.

Latest Patents

Among his latest achievements, Han has developed pyrrolopyrrole compositions as pyruvate kinase (PKR) activators. This innovation focuses on modulating pyruvate kinase to create novel chemical compounds that serve as activators of PKR. The applications of these compounds are significant, particularly in treating diseases and disorders associated with PKR and PKM2, including pyruvate kinase deficiency (PKD), sickle cell disease (SCD), and thalassemia. Additionally, he has made strides in treating sickle cell disease with pyruvate kinase R activating compounds, presenting methods and compositions, including a therapeutic compound designated as Compound 1.

Career Highlights

Bingsong Han's career includes key positions in notable companies such as Forma Therapeutics, Inc. and Valo Health, Inc. His work within these organizations has facilitated significant advancements in therapeutic drug development.

Collaborations

Throughout his impressive career, Han has collaborated with several distinguished professionals, including Xiaozhang Zheng and David R Lancia, Jr. Their collective expertise has driven innovative approaches in their research endeavors.

Conclusion

In summary, Bingsong Han's extensive work and innovation in the field of pyruvate kinase research underline his commitment to advancing medical science. With numerous patents and ongoing collaborations, Han continues to make a significant impact, paving the way for potentially groundbreaking treatments for various health conditions.

Profile summary based on public USPTO records.